GRASS (Grass MATA MPL Real-world Assessment Study)
ConditionGrass Pollen Allergy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAllergy Therapeutics
About this trial
Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.
Eligibility criteria
Qualifiers
are male and female patients
are 18 years of age or older
treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
Patients will only be enrolled in the study after the treatment decision has been made
Disqualifiers
Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.
In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.
Trial design
Treatments tested in this trial
- Grassmuno®
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Allergy Therapeutics
Lead sponsor
Bencard Allergie GmbH
Collaborator
ClinCompetence Cologne GmbH
Collaborator
Source ClinicalTrials.gov